Kazunori Inabe

Title: Kazunori Inabe: Innovator in Pharmaceutical Composition

Introduction

Kazunori Inabe is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceutical compositions, particularly in the area of insulin resistance and carbohydrate metabolism. With a total of 2 patents, Inabe's work is paving the way for advancements in medical treatments.

Latest Patents

Inabe's latest patents include a novel polypeptide that binds to Akt2, which is instrumental in screening agents that improve insulin resistance and carbohydrate metabolism. This polypeptide is expressed in fat cells and, when overexpressed, reduces the activity of Akt2. The associated polynucleotide encodes this polypeptide, and the expression vector includes the polynucleotide. Additionally, Inabe has developed a method for producing a pharmaceutical composition that utilizes the active ingredient obtained from the screening method. His second patent involves a cap-binding protein, which is also a polypeptide useful for screening agents that improve insulin resistance and glucose metabolism. This protein is expressed in skeletal muscle and inhibits sugar incorporation into cells when overexpressed.

Career Highlights

Kazunori Inabe is currently employed at Astellas Pharma GmbH, where he continues to innovate in the pharmaceutical sector. His research focuses on developing methods and compositions that can significantly impact the treatment of metabolic disorders.

Collaborations

Inabe has collaborated with notable coworkers such as Yoshitaka Ueda and Hideki Endoh, contributing to a dynamic research environment that fosters innovation.

Conclusion

Kazunori Inabe's work in developing pharmaceutical compositions for insulin resistance and carbohydrate metabolism showcases his dedication to advancing medical science. His innovative patents and collaborations highlight his significant role in the field.